首页> 外文期刊>Vaccine >Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice.
【24h】

Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice.

机译:弗氏志贺氏菌外膜囊泡的粘膜免疫诱导了对小鼠的保护。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Vaccination appears to be the only rational prophylactic approach to control shigellosis. Unfortunately, there is still no safe and efficacious vaccine available. We investigated the protection conferred by a new vaccine containing outer membrane vesicles (OMVs) from Shigella flexneri with an adjuvant based on nanoparticles in an experimental model of shigellosis in mice. OMVs were encapsulated in poly(anhydride) nanoparticles prepared by a solvent displacement method with the copolymer PMV/MA. OMVs loaded into NPs (NP-OMVs) were homogeneous and spherical in shape, with a size of 197 nm (PdI=0.06). BALB/c mice (females, 9-week-old, 20+or-1 g) were immunized by intradermal, nasal, ocular (20 micro g) or oral route (100 micro g) with free or encapsulated OMV. Thirty-five days after administration, mice were infected intranasally with a lethal dose of S. flexneri (1x107 CFU). The new vaccine was able to protect fully against infection when it was administered via mucosa. By intradermal route the NP-OMVs formulation increased the protection from 20%, obtained with free extract, to 100%. Interestingly, both OMVs and OMV-NP induced full protection when administered by the nasal and conjuntival route. A strong association between the ratio of IL-12p40/IL-10 and protection was found. Moreover, low levels of IFN- gamma correlate with protection. Under the experimental conditions used, the adjuvant did not induce any adverse effects. These results place OMVs among promising candidates to be used for vaccination against Shigellosis.
机译:接种疫苗似乎是控制志贺菌病的唯一合理预防方法。不幸的是,仍然没有可用的安全有效的疫苗。在小鼠志贺氏菌病的实验模型中,我们研究了一种新疫苗所赋予的保护作用,该疫苗含有来自志贺氏志贺氏菌的外膜囊泡(OMV)和基于纳米粒子的佐剂。将OMV封装在通过溶剂置换法和共聚物PMV / MA制备的聚(酸酐)纳米颗粒中。加载到NP中的OMV(NP-OMV)是均匀的球形,大小为197 nm(PdI = 0.06)。 BALB / c小鼠(雌性,9周龄,20+或-1 g)通过皮内,鼻,眼(20微克)或口服途径(100微克)用游离或封装的OMV免疫。给药后三十五天,用致死剂量的iS鼻内感染小鼠。 flexneri (1x10 7 CFU)。当通过粘膜给药时,新疫苗能够完全保护免受感染。通过皮内途径,NP-OMVs制剂将保护作用从游离提取物获得的20%提高到100%。有趣的是,当通过鼻和结膜途径给药时,OMV和OMV-NP均可诱导完全保护。发现IL-12p40 / IL-10的比例与保护之间有很强的联系。而且,低水平的IFN-γ与保护有关。在所使用的实验条件下,佐剂不会引起任何不良作用。这些结果使OMV成为有希望用于抗志贺氏菌病疫苗的候选者之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号